Bladder Cancer Weekly

March 23, 2026

Videos

Peer-to-Peer Clinical Conversations

Revisiting Radiation for Non-Muscle-Invasive Bladder Cancer - Ananya Choudhury

Ananya Choudhury reviews radiation therapy for non-muscle invasive bladder cancer, citing 1990s UK trials showing overlapping Kaplan-Meier curves between radiotherapy and standard care.

ctDNA to Guide Response-Adapted Bladder Preservation in MIBC: Investigating a Strategy from the Integrated RETAIN Trials Analysis - Pooja Ghatalia

Pooja Ghatalia

Pooja Ghatalia discusses pooled ctDNA analysis from the RETAIN-1 and RETAIN-2 trials involving 111 muscle-invasive bladder cancer patients.

Beyond the Abstracts

Contemporary Practice Patterns in Female Radical Cystectomy: Results of a UK and Ireland Survey - Beyond the Abstract

Urinary Tumor DNA-based Liquid Biopsy in Bladder Cancer Management: A Systematic Review - Beyond the Abstract

Conference Coverage

SES AUA 2026: First Results from CORE-008 Cohort A: A Phase 2 Study of Intravesical Cretostimogene Grenadenorepvec in Patients with High Risk BCG-Naïve NMIBC

SES AUA 2026: UGN-102 for Low-Grade Intermediate Risk Non Muscle Invasive Bladder Cancer: 5-Year Long-Term Extension Study Results from the Single-Arm, Phase 2B OPTIMA II Study

EAU 2026: RECURxNCE-BCa, an Artificial Intelligence-based Tool to Predict Recurrence in Nonmuscle Invasive Bladder Cancer Using the WHO 2004/2022 Grading System

EAU 2026: Urinary Markers versus Cystoscopy: Is It Time to Ditch the Scope?

ASCO GU 2026: Sasanlimab + BCG in BCG-Naïve High Risk NMIBC: Exploratory Biomarker Analysis of the Phase 3 CREST Trial

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Tissue Penetration of Gemcitabine and Gemcitabine Phosphate Metabolites Following Gemcitabine Intravesical System Administration Versus Standard Intravesical Instillation in a Preclinical Minipig Model.

DaBlaCa-13 Study: Five-year Follow-up from the Randomized Controlled Trial of Chemoresection with Intravesical Mitomycin C in Recurrent Ta Non-muscle-invasive Bladder Cancer.

Blood and Urine Circulating Tumor DNA in Urothelial Bladder Cancer: State of the Art and Clinical Perspective.

Impact of Intravesical BCG Therapy on Quality of Life in Non-Muscle-Invasive Bladder Cancer: A Prospective Evaluation Using The FACT-Bl Questionnaire.

Prognostic Factors and Oncological Outcomes after Trimodality Bladder-Preserving Therapy for Muscle-Invasive Bladder Cancer: A Multicenter Real-World Study.

Population-based outcomes of chemoradiation therapy for muscle-invasive bladder cancer in older adults.

Development and validation of a tumor-derived CXCL1 qPCR assay to support patient selection for anti-CXCL1 therapeutics in bladder cancer.

Bladder Preservation Strategies in Muscle-Invasive Bladder Cancer.

Preoperative ctDNA Predicts Upstaging and Recurrence in High-Risk Non-Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy.

Clinical complete response as a surrogate for pathological response in bladder cancer: a systematic review and meta-analysis.

Liver metastases in advanced urothelial carcinoma (ARON-2): do pembrolizumab and avelumab make a difference in a poor-prognosis scenario?

The Role of Socioeconomic Status in Influencing Stage at Presentation and Overall Survival in Bladder Cancer: Experience From the West of Scotland.

Risk stratification and conditional recurrence after radical cystectomy: toward adaptive follow-up.

Curriculum-based training improves transurethral resection of bladder tumour performance compared to conventional training: the EuropeaN Training in uRologY (ENTRY) project.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2026 Digital Science Press, LLC